Elanco Animal Health (ELAN) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic Positioning and Market Outlook

• Positioned as a top-tier global animal health company with a balanced portfolio across pet and farm animal segments, serving over 90 countries and generating 55% of revenue internationally.

• Positioned for sustained mid-single-digit growth in 2025, accelerating further in 2026, driven by a robust innovation pipeline and a stabilized base business.

• The animal health market is valued at ~$41B, with consistent mid-single digit growth driven by pet humanization, global protein demand, and global expansion.

• Focused on growth, innovation, and cash, with a methodical strategy since IPO, including major acquisitions and a shift to an independent, innovation-led company.

• Expansion into environmental value with a One Health platform and a new carbon inset market for cattle, enabling dairy farmers to earn $10M in credits.

Innovation and Product Pipeline

• Six to seven potential blockbuster products are expected to contribute $600–$700M in incremental revenue in 2025, including Zenrelia, Credelio Quattro, AdTab, Bovaer, and Experior.

• Zenrelia is showing strong launch momentum in the global canine dermatology market, with rapid clinic adoption and international expansion, supported by a direct-to-consumer campaign.

• Credelio Quattro is launching into the fast-growing US endecto parasiticide segment, with differentiated features and enhanced competitiveness.

• Bovaer, a methane-reducing feed ingredient, is driving sustainability in dairy, with over 900K cows enrolled and multiple CPG contracts for carbon credits.

• Life cycle management and next-generation R&D focus on pet parasiticides, dermatology, pain, and livestock sustainability.

Financial Performance and Operational Efficiency

• 2024 revenue guidance midpoint is $4.44B, with adjusted EBITDA of $915M and adjusted EPS of $0.92.

• Achieved 1% organic growth in 2023, guiding to 3% in 2024, and targeting mid-single-digit growth in 2025.

• Gross debt reduction of $1.45B expected in 2024, with net leverage targeted below 3x over time.

• Gross margin expected to improve as new products scale, with targeted price increases and cost efficiencies in SG&A.

• 2025 is a major investment year for launches, with profitability expected to accelerate in 2026 as operating leverage increases.